Ketul R Chaudhary1,2, Yupu Deng1, Colin M Suen1,2, Mohamad Taha1,2, Thomas H Petersen3, Shirley H J Mei1, Duncan J Stewart1,2. 1. Sinclair Centre for Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada. 2. Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. 3. United Therapeutics Corp., Research Triangle Park, NC, USA.
Abstract
BACKGROUND AND PURPOSE: Pulmonary arterial hypertension (PAH) is a life-threatening disease that leads to progressive pulmonary hypertension, right heart failure and death. Parenteral prostaglandins (PGs), including treprostinil, a prostacyclin analogue, represent the most effective medical treatment for severe PAH. We investigated the effect of treprostinil on established severe PAH and underlying mechanisms using the rat SU5416 (SU, a VEGF receptor-2 inhibitor)-chronic hypoxia (Hx) model of PAH. EXPERIMENTAL APPROACH: Male Sprague Dawley rats were injected with SU (20 mg·kg-1 , s.c.) followed by 3 weeks of Hx (10% O2 ) to induce severe PAH. Four weeks post-SU injection, baseline right ventricular (RV) systolic pressure (RVSP) was measured, and the rats were randomized to receive vehicle or treprostinil treatment (Trep-100: 100 ng·kg-1 ·min-1 or Trep-810: 810 ng·kg-1 ·min-1 ). Following 3 weeks of treatment, haemodynamic and echocardiographic assessments were performed, and tissue samples were collected for protein expression and histological analysis. KEY RESULTS: At week 7, no difference in RVSP or RV hypertrophy was observed between vehicle and Trep-100; however, Trep-810 significantly reduced RVSP and RV hypertrophy. Trep-810 treatment significantly improved cardiac structure and function. Further, a short-term infusion of treprostinil in rats with established PAH at 4 weeks post-SU produced an acute, dose-dependent reduction in RVSP consistent with a vasodilator effect. However, chronic Trep-810 treatment did not alter media wall thickness, degree of vascular occlusion or total vessel count in the lungs. CONCLUSIONS AND IMPLICATIONS: Treprostinil exerts therapeutic benefits in PAH through decreased vascular resistance and improved cardiac structure and function; however, treprostinil treatment does not have direct impact vascular remodelling.
BACKGROUND AND PURPOSE:Pulmonary arterial hypertension (PAH) is a life-threatening disease that leads to progressive pulmonary hypertension, right heart failure and death. Parenteral prostaglandins (PGs), including treprostinil, a prostacyclin analogue, represent the most effective medical treatment for severe PAH. We investigated the effect of treprostinil on established severe PAH and underlying mechanisms using the ratSU5416 (SU, a VEGF receptor-2 inhibitor)-chronic hypoxia (Hx) model of PAH. EXPERIMENTAL APPROACH: Male Sprague Dawley rats were injected with SU (20 mg·kg-1 , s.c.) followed by 3 weeks of Hx (10% O2 ) to induce severe PAH. Four weeks post-SU injection, baseline right ventricular (RV) systolic pressure (RVSP) was measured, and the rats were randomized to receive vehicle or treprostinil treatment (Trep-100: 100 ng·kg-1 ·min-1 or Trep-810: 810 ng·kg-1 ·min-1 ). Following 3 weeks of treatment, haemodynamic and echocardiographic assessments were performed, and tissue samples were collected for protein expression and histological analysis. KEY RESULTS: At week 7, no difference in RVSP or RV hypertrophy was observed between vehicle and Trep-100; however, Trep-810 significantly reduced RVSP and RV hypertrophy. Trep-810 treatment significantly improved cardiac structure and function. Further, a short-term infusion of treprostinil in rats with established PAH at 4 weeks post-SU produced an acute, dose-dependent reduction in RVSP consistent with a vasodilator effect. However, chronic Trep-810 treatment did not alter media wall thickness, degree of vascular occlusion or total vessel count in the lungs. CONCLUSIONS AND IMPLICATIONS: Treprostinil exerts therapeutic benefits in PAH through decreased vascular resistance and improved cardiac structure and function; however, treprostinil treatment does not have direct impact vascular remodelling.
Authors: Mirjam E van Albada; Richard van Veghel; Adri H Cromme-Dijkhuis; Regien G Schoemaker; Rolf M F Berger Journal: J Cardiovasc Pharmacol Date: 2006-11 Impact factor: 3.105
Authors: Jose Gomez-Arroyo; Masahiro Sakagami; Aamer A Syed; Laszlo Farkas; Benjamin Van Tassell; Donatas Kraskauskas; Shiro Mizuno; Antonio Abbate; Harm J Bogaard; Peter R Byron; Norbert F Voelkel Journal: Eur Respir J Date: 2014-09-26 Impact factor: 16.671
Authors: Ketul R Chaudhary; Yupu Deng; Colin M Suen; Mohamad Taha; Thomas H Petersen; Shirley H J Mei; Duncan J Stewart Journal: Br J Pharmacol Date: 2018-09-16 Impact factor: 8.739
Authors: Sarah Holmboe; Asger Andersen; Jacob Johnsen; Jan Møller Nielsen; Rikke Nørregaard; Hans Erik Bøtker; Lucie H Clapp; Jens Erik Nielsen-Kudsk Journal: J Cardiovasc Pharmacol Date: 2017-01 Impact factor: 3.105
Authors: Sarah Holmboe; Asger Andersen; Mads D Vildbrad; Jan M Nielsen; Steffen Ringgaard; Jens E Nielsen-Kudsk Journal: Pulm Circ Date: 2013-12 Impact factor: 3.017
Authors: Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971
Authors: Ketul R Chaudhary; Yupu Deng; Colin M Suen; Mohamad Taha; Thomas H Petersen; Shirley H J Mei; Duncan J Stewart Journal: Br J Pharmacol Date: 2018-09-16 Impact factor: 8.739
Authors: Allison E Norlander; Melissa H Bloodworth; Shinji Toki; Jian Zhang; Weisong Zhou; Kelli Boyd; Vasiliy V Polosukhin; Jacqueline-Yvonne Cephus; Zachary J Ceneviva; Vivek D Gandhi; Nowrin U Chowdhury; Louis-Marie Charbonnier; Lisa M Rogers; Janey Wang; David M Aronoff; Lisa Bastarache; Dawn C Newcomb; Talal A Chatila; R Stokes Peebles Journal: J Clin Invest Date: 2021-04-01 Impact factor: 14.808